赫赛汀与阿霉素序贯联合应用对乳腺癌细胞抑制作用的研究

目的 探讨体外实验中赫赛汀(HER)与阿霉素(ADM)联合的最佳序贯方式；赫赛汀对于阿霉素作用的影响及机制.方法 利用MTT法及流式细胞技术测定HER、ADM不同序贯联合应用对人乳腺癌细胞(MDA-MB453)的抑制率及细胞周期的影响.结果 不同序贯方式联合应用组抑制率明显高于单药化疗组(P＜0.01),在化疗后12h或更长时间使用赫赛汀可取得协同作用.随着HER与ADM序贯方式的改变,G0/G1、S期比例逐渐下降,G2/M期比例逐渐升高.结论 应用阿霉素12h后使用赫赛汀可取得协同作用；序贯应用的差异与细胞周期的变化有一定关系.

Inhibitory effect of combined herceptin and adriamycin on human breast cancer cells

Objective To study the best consequence of combined herceptin(HER) and adriamycin(ADM) for breast cancer during in vitro experiment and the effect of HER on ADM and its mechanism.Methods Inhibition rate of combined HER and ADM on human breast cancer cell line(MDA-MB453) and its effect on cell cycle were detected by MTT and flow cytometry(FCM),respectively.Results The inhibition rate of combined HER and ADM was significantly higher than that of single ADM or HER therapy(P<0.05).The synergistic effect was achieved on breast cancer cells 12h or longer after HER therapy.Along with the change of ADM and HER sequence,the number of breast cancer cells was gradually decreased in G0/G1 and S phases,and gradually increased in G2/M phase.Conclusion Synergistic effects can be achieved on breast cancer cells when HER is used 12h after the use of ADM.The difference in sequence of HER and ADM application is related with the change of cell cycle.